VIVA: Vivity Outcomes in Patients With Early Stage Glaucoma
The goal of the study is to determine the visual outcomes in patients with mild, pre-perimetric glaucoma who undergo cataract surgery with implantation of the Alcon Vivity Extended Range Intraocular Lens (IOL).
Arms and Interventions
Patients implanted with Vivity or Vivity Toric intraocular lens at the time of cataract surgery.
Procedure: Cataract Surgery with Implantation of Vivity Extended Range of Vision IOL
Patients with early stage glaucoma implanted with Vivity or Vivity Toric IOL
Primary Outcome Measures
- Uncorrected Distance Visual Acuity [4-6 months]
- Uncorrected Intermediate Visual Acuity [4-6 months]
- Uncorrected Near Visual Acuity [4-6 months]
Secondary Outcome Measures
- Contrast Sensitivity [4-6 months]
As measured by Pelli Robson Chart
- Patient Satisfaction and Spectacle Independence Survey Results [4-6 months]
- Mean Refractive Spherical Equivalent [4-6 months]
Patients at least age 45 years of age undergoing uncomplicated cataract surgery with optional concomitant minimally invasive glaucoma surgery (MIGS)
Subjects with documented diagnosis of pre-perimetric glaucoma
Calculated lens power within Vivity/Vivity toric range
Willing and able to comprehend informed consent and complete 4-6 month post-op visit
Potential postoperative BCDVA of 20/20 or better in each eye based on Investigator's medical opinion
Ocular comorbidity, other than pre-perimetric glaucoma, that could reduce the potential postoperative BCDVA
Previous ocular surgery including refractive surgery
Subjects who are pregnant or plan to become pregnant during the course of the study.
Contacts and Locations
|1||Vance Thompson Vision||Sioux Falls||South Dakota||United States||57108|
Sponsors and Collaborators
- Vance Thompson Vision
- Principal Investigator: Brian M Shafer, MD, Vance Thompson Vision
Study Documents (Full-Text)None provided.